US FDA approves TTFields therapy as a treatment for mNSCLC. Read more
Pembrolizumab, amivantamab-vmjw, osimertinib, and nivolumab join the list of FDA-approved treatments for various lung cancer indications. Read more
At the end of 2023, the agency approved repotrectinib for ROS1+ NSCLC, granted priority review for tarlatamab for advanced SCLC, and asked for an additional confirmatory trial for sotorasib for KRAS G12C-mutated NSCLC. Read more
IASLC names J. Michael Hoehn COO. FDA approves adagrasib for KRAS G12C-mutated NSCLC. NHS England increases access to screening in effort to catch cancers earlier. Read more
Learn how new guidance from the UK’s National Institutes for Health Care Excellence addresses an unmet clinical need for patients with EGFR+ NSCLC with exon 20 insertion and stay up to date on the latest meeting news from IASLC. Read more
By Erik MacLaren, PhD Posted: August 21, 2020 The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Merck’s immune checkpoint inhibitor pembrolizumab, adding a new tissue-agnostic indication […] Read more
Posted: February 12, 2020 December 12, 2019—Stephen M. Hahn, MD, FASTRO, was confirmed as commissioner of the U.S. Food and Drug Administration by a Senate vote of 72 to 18. […] Read more
Posted: December 11, 2019 In June 2019, the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence launched Project Facilitate, a call center that assists oncology healthcare professionals with […] Read more
By Erik MacLaren, PhD Posted: April 1, 2019 On January 25, 2019, the Director of the National Cancer Institute (NCI) Norman E. Sharpless, MD, participated in a live social media event […] Read more
Posted: December 2018 Richard Pazdur, MD, is director of the U.S. Food and Drug Administration’s (FDA’s) Oncology Center of Excellence. Below, he discusses the current status of and future directions […] Read more